Improved dihydroergotamine (DHE) pharmacology following orally-inhaled delivery

被引：0
|
作者：
Cook, R. O. [1 ]
Shrewsbury, S. B. [1 ]
机构：
[1] MAP Pharmaceut Inc, Res & Dev, Mountain View, CA USA
来源：
HEADACHE | 2008年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S62 / S63
页数：2
相关论文
共 50 条
  • [1] Utility of Orally-Inhaled Dihydroergotamine When Early Intervention Is Impractical
    Kori, Shashidhar
    Tepper, Stewart
    Goadsby, Peter J.
    Winner, Paul
    Wang, Min
    Silberstein, Stephen
    ANNALS OF NEUROLOGY, 2011, 70 : S60 - S60
  • [2] Relationship Between Plasma Dihydroergotamine (DHE) Concentrations and the Occurrence of Nausea after Treatment with Orally Inhaled DHE
    Silberstein, S. D.
    Basile, A. S.
    Kellerman, D.
    Davar, G.
    HEADACHE, 2014, 54 : 13 - 13
  • [3] Orally Inhaled Dihydroergotamine: A Review
    Tepper, Stewart J.
    HEADACHE, 2013, 53 : 43 - 53
  • [4] Orally inhaled dihydroergotamine: A novel ergot delivery method for the treatment of migraine
    Phung, Olivia J.
    FORMULARY, 2012, 47 (02) : 54 - 57
  • [5] Orally inhaled dihydroergotamine: reviving and improving a classic
    Baron, Eric P.
    Tepper, Stewart J.
    FUTURE NEUROLOGY, 2011, 6 (03) : 327 - 333
  • [6] Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics
    Shrewsbury, Stephen B.
    Kori, Shashidhar H.
    Miller, S. David
    Pedinoff, Andrew
    Weinstein, Steven
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (07) : 1977 - 1985
  • [7] Comparison of the pharmacokinetics of STS101, an intranasal dry powder formulation of dihydroergotamine, with other intranasal, injectable, and orally inhaled DHE formulations
    Strom, Shannon
    Kollins, John
    Albrecht, Detlef
    CEPHALALGIA, 2019, 39 : 199 - 199
  • [8] ABOLITION OF HYPOTENSION FOLLOWING SPINAL-ANESTHESIA BY DIHYDROERGOTAMINE (DHE)
    ZIMPFER, M
    FITZAL, S
    TONCZAR, L
    ANAESTHESIST, 1979, 28 (04): : 43 - 47
  • [9] Reduced Adverse Event Profile of Orally Inhaled DHE (MAP0004) vs IV DHE: Potential Mechanism
    Cook, Robert O.
    Shrewsbury, Stephen B.
    Ramadan, Nabih M.
    HEADACHE, 2009, 49 (10): : 1423 - 1434
  • [10] The efficacy and tolerability of levadex™ (orally inhaled DHE) for the treatment of migraine in subjects with concomitant asthma
    Kellerman, D.
    Wolfe, J.
    Kori, S.
    Borland, S.
    Wang, M.
    Hu, B.
    Aurora, S.
    JOURNAL OF HEADACHE AND PAIN, 2010, 11 : S117 - S117
12345